The review comes amid escalating costs linked to athlete training, infrastructure development, equipment procurement, and ...

An international study has uncovered why a widely used treatment for acute myeloid leukemia (AML) doesn't work for everyone. The findings could help doctors better match patients with the therapies ...

Verastem Oncology (NASDAQ: VSTM) has recently announced positive updated safety and efficacy results from the ramp 205 phase 1/2 trial, which is evaluating avutometinib plus defactinib in combination ...

Verastem (VSTM) announced positive updated safety and efficacy results from the RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in ...

It has been known for years that there is a small subgroup of patients with colorectal cancer who have HER2-positive ...